Levofloxacin Has Limited and Unreliable Coverage Against Enterococcus Species
Levofloxacin should not be relied upon as primary therapy for Enterococcus infections, though it has FDA-approved indications for specific infections where E. faecalis may be present (complicated skin/soft tissue infections, complicated UTIs, and chronic bacterial prostatitis). The drug demonstrates poor and inconsistent activity against enterococci, particularly E. faecium, with high baseline resistance rates and significant clinical limitations.
FDA-Approved Indications Involving Enterococcus
According to the FDA label, levofloxacin is approved for:
- Complicated skin and skin structure infections due to E. faecalis 1
- Chronic bacterial prostatitis due to E. faecalis 1
- Complicated UTIs (10-day regimen) due to E. faecalis 1
However, these approvals do not indicate robust anti-enterococcal activity—rather, they reflect that E. faecalis may be present in polymicrobial infections at these sites.
Critical Limitations of Levofloxacin Against Enterococcus
Poor Intrinsic Activity
- Only 39% of vancomycin-susceptible enterococci and 11% of vancomycin-resistant enterococci were susceptible to levofloxacin in vitro 2
- Levofloxacin exhibits a marked inoculum effect against all enterococci, meaning activity decreases dramatically with higher bacterial loads 2
- These findings suggest levofloxacin is of limited use in serious enterococcal infections 2
High Resistance Rates
E. faecium shows particularly poor susceptibility:
- 87.8% resistance rate in Japanese hospital isolates 3
- Resistance mediated by multiple mutations in ParC/GyrA genes 3
E. faecalis demonstrates variable but concerning resistance:
- 56.8% susceptibility (43.2% resistance) in Kenyan isolates 4
- Only 10-26% resistance in global meta-analysis of non-clinical sources 5
- Resistance increases dramatically with hospital exposure and levofloxacin prophylaxis 6
Species-Specific Differences
E. faecalis generally shows better susceptibility than E. faecium, but neither species should be considered reliably covered 3, 4, 7.
Clinical Implications and Pitfalls
When Levofloxacin Might Be Considered
- Uncomplicated UTIs where E. faecalis is isolated and proven susceptible
- Polymicrobial infections where levofloxacin targets other pathogens (gram-negatives, atypicals) and enterococcus is a minor component
- Only after susceptibility testing confirms activity
Critical Warnings
- Never use empirically for suspected enterococcal bacteremia or endocarditis - resistance rates are too high and inoculum effect makes treatment unreliable 2
- Hospital-acquired infections: Resistance rates approach 88% in E. faecium from hospitalized patients 3
- Levofloxacin prophylaxis selects for resistant enterococci: Patients on fluoroquinolone prophylaxis develop intestinal colonization with ampicillin-resistant, levofloxacin-resistant E. faecium high-risk clones 6
Recommended Alternatives for Enterococcal Infections
Based on current guidelines 8:
For VRE or suspected resistant enterococci:
- Linezolid 600 mg IV/PO q12h (first-line recommendation) 8
- High-dose daptomycin 8-12 mg/kg/day ± β-lactams for bacteremia 8
- Tigecycline for intra-abdominal infections 8
For susceptible E. faecalis:
- Ampicillin remains the drug of choice when susceptible 8
- High-dose ampicillin (18-30g IV daily) may overcome resistance in UTIs 8
For uncomplicated UTIs due to VRE:
Bottom Line
Levofloxacin has FDA approval for certain infections where E. faecalis may be present, but this does not translate to reliable clinical coverage. With resistance rates of 43-88% depending on species and setting, plus a significant inoculum effect, levofloxacin should not be considered adequate coverage for enterococcal infections unless susceptibility is confirmed. For empiric therapy targeting enterococci, use linezolid, daptomycin, or ampicillin (if susceptibility likely) instead 8, 2.